Recombinant Human BTNL8 Fc Chimera Protein, CF

Recombinant Human BTNL8 Fc Chimera (Catalog #9359-BT) enhances anti-CD3-induced IFN-gamma secretion by mouse CD3+ T cells. The ED50 forthis effect is0.5-2.5 μg/mL.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human BTNL8 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to enhance anti-CD3-induced IFN-gamma secretion of mouse CD3⁺ T cells. The ED₅₀ for this effect is 0.5-2.5 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human BTNL8 protein
  

  Human BTNL8 (Gln18-Lys238) Accession # Q6UX41-1	IEGRMD	Human IgG1 (Pro100-Lys330)
  N-terminus		C-terminus

• Accession #: Q6UX41-1
• N-terminal Sequence: No results obtained. Gln18 inferred from enzymatic pyroglutamate treatment revealing Trp19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Purity Statement: Antigen Affinity-purified
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 52 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 53-63 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS and Tween® 80.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 200 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human BTNL8 Fc Chimera Protein, CF

• BTN9.2
• BTNL8
• butyrophilin-like 8
• butyrophilin-like protein 8
• UNQ702/PRO1347

Background

Butyrophilin-like 8 (BTNL8) is a member of the BTN/MOG Ig-superfamily and functions as a negative regulator of immune cell activation (1). Human BTNL8 is a 500 amino acid (aa) type I transmembrane glycoprotein that contains a signal peptide followed by an extracellular domain (ECD), a transmembrane region and a short cytoplasmic domain (2). The ECD of human BTNL8 shares 88% sequence identity with the ECD of mouse BTNL8. BTNL8 has two alternatively spliced forms: B7-like and BTN-like. Both isoforms of BTNL8 are expressed in a range of human tissues (3). The complete immunological function of BTNL molecules is only beginning to emerge. BTNL8 has been shown to be important in initiation of primary immune responses, suggesting a role in priming of naïve T lymphocytes (3). Down-regulation of BNTL8 mRNA levels has been associated with ulcerative colitis and colon cancer (4). BTNL8 are expressed in colon, lung, testis and neutrophils, and its expression is significantly decreased in ulcerative colitis, colonic tumors as compared to unaffected tissue (4). Soluble BTNL8-Fc fusion protein binds to resting, but not activated T cells. In vitro, BTNL8 co-stimulates T cell proliferation and cytokine production. In vivo injections of BTNL8-Fc significantly increases production of
Ag-specific IgG during the primary but not the secondary immune response (3).

1. Arnett, H.A. et al. (2007) J. Immunol. 178:1523.
2. Arnett, H.A. et al. (2009) Cytokine 46:370.
3. Chapoval, A.I. et al. (2013) Mol Immunol. 56:819.
4. Lebrero-Fernández C. et al. (2016) Immun Inflamm Dis. 4:191.

Bioinformatics

• Uniprot:
  • Q6UX41-1()